Ketotifen Fumarate

Category	Influenza Virus
CAS	34580-14-8
Description	Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis,or the itchy red eyes caused by allergies. In its oral form, it is used to preventasthma attacks.

Quotation Now

Product Information

Synonyms	Zaditen; Zaditor
IUPAC Name	(E)-but-2-enedioic acid;2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
Molecular Weight	425.5
Molecular Formula	C19H19NOS.C4H4O4
Canonical SMILES	CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1.C(=CC(=O)O)C(=O)O
InChI	InChI=1S/C19H19NOS.C4H4O4/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19;5-3(6)1-2-4(7)8/h2-5,8,11H,6-7,9-10,12H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
InChIKey	YNQQEYBLVYAWNX-WLHGVMLRSA-N
Boiling Point	250-263 °C(lit.)
Melting Point	>191°C (dec.)
Flash Point	96-98°C/5mm
Purity	>98%
Density	0.968 g/mL at 25 °C(lit.)
Solubility	In Vitro: DMSO : ≥ 100 mg/mL(235.02 mM) H2O : 16.67 mg/mL(39.18 mM;Need ultrasonic) In Vivo: 1.Add each solvent one by one:PBS Solubility: 37.5 mg/mL (88.13 mM); Clear solution; Need ultrasonic 2.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.88 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (5.88 mM); Clear solution
Appearance	Off-white crystalline powder
Application	Antipruritics
Storage	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months -20°C, 1 month (sealed storage, away from moisture)
Complexity	595
Exact Mass	425.12969401
Index Of Refraction	n20/D 1.522(lit.)
In Vitro	Ketotifen (0-100 μM; 2 or 4 days) inhibits SARS-CoV-2 with an EC50 of 48.9 μM; and increases the percentage inhibition of SARS-CoV-2 to 79%, 83% and 93% when co-administers with 25, 50 and 100 μM Indomethacin, respectively. Ketotifen (0-50 μM; 24 h) has inhibitory activity against PR8, pH1N1 and H3N2 with EC50s of 5.9 μM, 33.7 μM and 48.5 μM, respectively; and exhibits relatively low cytotoxicity in MDCK cells (EC50=291 μM).
In Vivo	Ketotifen (80 mg/kg; i.g.; daily for 3 days) reduces end organ damage and mortality in mice infected with influenza virus. Ketotifen (0.4 mg/kg; i.p.; daily for 10 days) reduces encephalomyelitis (EAE) prevalence and severity. Animal Model: Female C57BL/6 mice (4-6 weeks; intranasal infection with 1×103 TCID50 of PR8 in 30 μL of DMEM) Dosage: 80 mg/kg Administration: i.g.; daily for 3 days Result: Reduced end organ damage and mortality in infected mice. Animal Model: Female C57BL/6 mice (5-6 weeks old; subcutaneously immunized with 150 μg of MOG35-55 peptide containing 4 mg/mL of Mycobacterium tuberculosis).
PSA	123.15000
Target	Histamine 1, SARS-CoV-2, Influenza virus